Title Amino Acid Polymorphism in the Reverse Transcriptase Region of Hepatitis B Virus and the Relationship With Nucleos(t)ide Analogues Treatment for Preventing Mother-to-Infant Transmission
Authors Chen, Jie
Yan, Ling
Zhu, Feng-Cai
Liu, Jian-Xun
Li, Rong-Cheng
Wang, Fu-Zhen
Li, Jie
Zhuang, Hui
Affiliation Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Microbiol, Beijing 100871, Peoples R China.
Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Ctr Infect Dis, Beijing 100871, Peoples R China.
Jiangsu Prov Ctr Dis Control & Prevent, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China.
Zhengzhou Municipal Ctr Dis Control & Prevent, Dept Major Projects, Zhengzhou, Peoples R China.
Guangxi Zhuang Autonomous Reg Ctr Dis Control & P, Nanning, Peoples R China.
Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
38 Xueyuan Rd, Beijing 100191, Peoples R China.
Keywords hepatitis B virus
reverse transcriptase
nucleos(t)ide analogues
perinatal transmission
ANTIVIRAL RESISTANCE MUTATIONS
TREATMENT-NAIVE PATIENTS
SURFACE-ANTIGEN
PERINATAL TRANSMISSION
FAMCICLOVIR RESISTANCE
VERTICAL TRANSMISSION
POLYMERASE MUTATIONS
VACCINATION PROGRAM
LAMIVUDINE THERAPY
TREATMENT FAILURE
Issue Date 2014
Publisher 医学病毒学杂志
Citation JOURNAL OF MEDICAL VIROLOGY.2014,86,(8),1288-1295.
Abstract A high maternal serum hepatitis B virus (HBV) DNA level is associated with vaccine failure. The administration of nucleos(t)ide analogues (NAs) in pregnancy for decreasing serum HBV is regarded as an effective and safe method to reduce HBV perinatal transmission. However, the effect of NAs treatment is closely related to amino acid polymorphisms in the HBV reverse transcriptase (RT) region. The full-length RT coding region of 334 HBV isolates from untreated Chinese women of childbearing age with persistent HBV infection were sequenced and amino acid polymorphic analysis was performed to evaluate its impact on NAs treatment for decreasing HBV perinatal transmission. Of the 334 isolates, 36 (10.8%) harbored NAs resistance (NAr) mutations which were mainly putative drug mutations related to lamivudine. The primary drug mutation rtA181T/V was detected in three HBeAg-negative women with an HBV DNA level of <4 log IU/ml. These NAr mutations were rarely detected in women with an HBV DNA level of >= 7 log IU/ml (P = 0.014) or in women younger than 35 years (P = 0.001). The NAr mutation rate among young women (<35 years) who had a high HBV DNA level (>= 7 log IU/ml) was significantly lower than in women who had lower HBV DNA levels (<7 log IU/ml) or who were older (>= 35 years; P = 0.017). These results suggest that younger women with a high HBV DNA level harbor fewer NAr mutations and that this population may respond to NAs treatment for the prevention of mother-to-infant transmission. (C) 2014 Wiley Periodicals, Inc.
URI http://hdl.handle.net/20.500.11897/189463
ISSN 0146-6615
DOI 10.1002/jmv.23948
Indexed SCI(E)
PubMed
Appears in Collections: 基础医学院

Web of Science®


6

Checked on Last Week

Scopus®



Checked on Current Time

百度学术™


0

Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.